Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 5,272 matching trials from the live ClinicalTrials.gov search.
Filters: Gainesville, Florida Clear all
Completed Phase 3 Interventional Results available

Gemcitabine With or Without Radiation Therapy in Treating Patients With Pancreatic Cancer

NCT00057876
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Gemcitabine, radiation therapy
Drug · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
228
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Fresno, California + 164 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)

NCT02500381
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
SRP-4045, SRP-4053, Placebo
Drug
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
6 Years to 13 Years · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
23
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Oct 25, 2026, 2:09 PM EDT
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Other · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer

NCT02003209
View directory record Official record
Conditions
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure, Docetaxel, Goserelin Acetate, Laboratory Biomarker Analysis, Pertuzumab, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, Whole Breast Irradiation
Drug · Other · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
731
States / cities
Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 2:09 PM EDT
Completed No phase listed Observational Results available

Airway Protective Mechanisms in PD (R01)

NCT03321019
View directory record Official record
Conditions
Parkinson Disease
Interventions
Capsaicin, Resistive respiratory loads, Event-related evoked potential using electroencephalography (EEG)., Fluoroscopic swallow evaluation
Drug · Device · Other + 1 more
Lead sponsor
University of Florida
Other
Eligibility
45 Years to 85 Years
Enrollment
119 participants
Timeline
2017 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 25, 2026, 2:09 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

NCT06660667
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
SAR402663, Diluent
Biological · Drug
Lead sponsor
Sanofi
Industry
Eligibility
50 Years to 90 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
24
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Bakersfield, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 2:09 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

NCT04437511
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
60 Years to 85 Years
Enrollment
1,736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
185
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 146 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Not applicable Interventional Results available

Comparison of Breathing Event Detection by a Continuous Positive Airway Pressure Device to Clinical Polysomnography

NCT00836758
View directory record Official record
Conditions
Sleep Apnea
Interventions
Analysis with AED and manual PSG scoring
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 75 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Phase 1 Interventional

Safety Study to Evaluate the Effects of Mild and Moderate Renal Impairment on the Pharmacokinetics of ABT-335 and Rosuvastatin When Administered Concomitantly

NCT00585143
View directory record Official record
Conditions
Dyslipidemia, Renal Insufficiency
Interventions
ABT-335, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
6
States / cities
Gainesville, Florida • Miami, Florida • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2012 · Synced Oct 25, 2026, 2:09 PM EDT
No Longer Available No phase listed Expanded access

Dichloroacetate Treatment of Congenital Lactic Acidosis Phase B: Expanded Access

NCT01797276
View directory record Official record
Conditions
Mitochondrial Enzyme Deficiencies
Interventions
Dichloroacetate
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 25, 2026, 2:09 PM EDT
Recruiting Phase 1 Interventional

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

NCT06352359
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
ONC-841
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Sacramento, California • Gainesville, Florida • Kissimmee, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

NCT00556959
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
high dose clonidine HCl sustained release, low dose clonidine HCl sustained release, placebo
Drug
Lead sponsor
Addrenex Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
13
States / cities
Gainesville, Florida • Jacksonville, Florida • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 25, 2026, 2:09 PM EDT
Active, not recruiting Not applicable Interventional

Innovative Multimodal and Attention Training to Improve Emotion Communication in Veterans With TBI and PTSD

NCT05478759
View directory record Official record
Conditions
Brain Injury, Post Traumatic Stress Disorder
Interventions
Multimodal affect recognition training, Attention Training, Brain Health Workshop, National Geographic Movies
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
25 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Not applicable Interventional Results available

Chronicle Offers Management to Patients With Advanced Signs and Symptoms of Heart Failure (COMPASS-HF)

NCT00643279
View directory record Official record
Conditions
Heart Failure
Interventions
Chronicle Implantable Hemodynamic Monitor, Standard of Care
Device · Other
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Loma Linda, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 25, 2026, 2:09 PM EDT
Recruiting Not applicable Interventional

Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients

NCT05732779
View directory record Official record
Conditions
Heart Transplant Rejection, Immune Suppression, Pediatric Heart Transplant, Medication Nonadherence, Health Behavior, Remote Monitoring, Patient Engagement
Interventions
DOT intervention
Other
Lead sponsor
University of Florida
Other
Eligibility
10 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Coral Gables, Florida • Gainesville, Florida • Hollywood, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

Dosing Flexibility Study in Patients With Rheumatoid Arthritis

NCT00580840
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
50
States / cities
Huntsville, Alabama • Montgomery, Alabama • Gilbert, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2018 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

NCT04423718
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Phase 4 Interventional Results available

Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

NCT02586623
View directory record Official record
Conditions
Symptomatic Neurogenic Orthostatic Hypotension
Interventions
Droxidopa capsules, Placebo capsules
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
18 Years and older
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
168
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 103 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

NCT02942017
View directory record Official record
Conditions
Postpartum Depression
Interventions
Placebo, SAGE-547 90 μg/kg/h
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
32
States / cities
Chandler, Arizona • Rogers, Arkansas • Lemon Grove, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Phase 3 Interventional

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

NCT00003313
View directory record Official record
Conditions
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Oral Complications, Radiation Toxicity
Interventions
filgrastim, amifostine trihydrate, carboplatin, paclitaxel, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2010
U.S. locations
244
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 191 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Not applicable Interventional

Mobile Decision Support System for Nurse Management of Neuromodulation Therapy

NCT02474459
View directory record Official record
Conditions
Parkinson's Disease
Interventions
iPad-Based Clinical Support Care, Standard Clinical Care
Device · Other
Lead sponsor
University of Utah
Other
Eligibility
30 Years to 75 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
6
States / cities
San Francisco, California • Gainesville, Florida • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2020 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

NCT01970878
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
110
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 25, 2026, 2:09 PM EDT
Completed Not applicable Interventional Results available

Pivotal Study Of A Dual Epicardial & Endocardial Procedure (DEEP) Approach

NCT02393885
View directory record Official record
Conditions
Atrial Fibrillation, Persistent or Longstanding Persistent Atrial Fibrillation
Interventions
AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
15
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 25, 2026, 2:09 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Developing a Non-invasive Cardiac Functional Health Status Measurement Device

NCT01877343
View directory record Official record
Conditions
Heart Failure
Interventions
CVInsight(TM)
Device
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 74 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 10, 2016 · Synced Oct 25, 2026, 2:09 PM EDT